<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01997294</url>
  </required_header>
  <id_info>
    <org_study_id>RJH20130115</org_study_id>
    <secondary_id>2011BAI11B05</secondary_id>
    <nct_id>NCT01997294</nct_id>
  </id_info>
  <brief_title>Sequential Therapy of Atorvastatin Improve Outcomes of ST-elevated Acute Myocardial Infarction</brief_title>
  <official_title>Sequential Therapy of Atorvastatin Improving Tissue Reperfusion and Clinical Outcomes of ST-elevated Acute Myocardial Infarction Study（The STRAIT Study）</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Zhang Qi, MD</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Shanghai Jiao Tong University School of Medicine</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Statins have been approved to benefit patients underwent percutaneous coronary intervention
      (PCI). The current study is designed to evaluate the effectiveness and safety of Sequential
      Therapy of Atorvastatin in patients with ST-elevated myocardial infarction and receive PCI
      treatment.
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>January 2013</start_date>
  <completion_date type="Anticipated">February 2017</completion_date>
  <primary_completion_date type="Anticipated">February 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Major Adverse Events (MACE) Occourance Rate</measure>
    <time_frame>30 days</time_frame>
    <description>Cardiac Death (CD)
Non-fatal re-inarction (CK-MB, cTNI or cTNT elevation again and over 3 times higher than up normal limit accompanied with syptoms or EKG indication)
revascularization driven by syptoms (CABG or re-PCI)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Secondary Endpoints</measure>
    <time_frame>12 months</time_frame>
    <description>TMP and TIMI grade chage after stents implantation; EKG ST reduction
MACE ( same definition as primary endpoints)</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Safty Endpoints</measure>
    <time_frame>12 months</time_frame>
    <description>Impairment of liver and kidney function
Other adverse events related to statin use</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">1200</enrollment>
  <condition>Acute Myocardial Infarction</condition>
  <arm_group>
    <arm_group_label>sequential therapy group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>80mg atorvastatin before primary PCI (PPCI) followed by 40mg/d for 7 days after PPCI followed by 20mg/d for 1 year</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Usual Therapy of atorvastatin</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>20mg/d before and after PPCI for 1 year</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sequential therapy of atorvastatin</intervention_name>
    <description>80mg atorvastatin before PPCI and 40mg/d for 7 days after PPCI</description>
    <arm_group_label>sequential therapy group</arm_group_label>
    <arm_group_label>Usual Therapy of atorvastatin</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Sighed informed consent

          -  Diagnosised as acute myocardial infarction

          -  Time frame less than 12 hours since the occurance of chest pain

          -  Aggred to receive sirolimus-eluted coronary stents

          -  Patients willing to accepte follow-up

        Exclusion Criteria:

          -  Allegy to statins or with a history against statin therapy

          -  Allegy to any products that will be used during PPCI

          -  Disagreed to receive PPCI and other related therapy

          -  Existing sever liver dysfuntion that statins can not be used according to the
             guildlines

          -  Sever kidney dysfunction (creatinine &gt;3mg/dl or eGFR&lt;30ml/min)

          -  Sever left ventricular dysfunction (Killip grade 3)

          -  Patients are currently taking medicine that may influence the use of statin

          -  Patients with a history of alcohol abuse or durg abuse

          -  Woman during pregnancy or lactation

          -  Patients who has attended other clinical trials

          -  Patients who has received PCI or CABG previously

          -  Patients who can not agree to accept study protocol

          -  Other conditions that may not sutible for the current study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Weifeng Shen, MD. PhD.</last_name>
    <role>Study Director</role>
    <affiliation>Institute of Cardiovascular Diseases, School of Medicine, Shanghai Jiao Tong University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Ruijin Hospital, Dept. of Cardiology</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200025</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <link>
    <url>http://cdc.rocksh.cn/</url>
    <description>website provided by CRO</description>
  </link>
  <verification_date>October 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 22, 2013</study_first_submitted>
  <study_first_submitted_qc>November 27, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 28, 2013</study_first_posted>
  <last_update_submitted>October 9, 2016</last_update_submitted>
  <last_update_submitted_qc>October 9, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 11, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Shanghai Jiao Tong University School of Medicine</investigator_affiliation>
    <investigator_full_name>Zhang Qi, MD</investigator_full_name>
    <investigator_title>Visa Chief of Department of Cardiology</investigator_title>
  </responsible_party>
  <keyword>sequential therapy</keyword>
  <keyword>atorvastatin</keyword>
  <keyword>acute myocardial infarction</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infarction</mesh_term>
    <mesh_term>Myocardial Infarction</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atorvastatin Calcium</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

